We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Try the New Site
We're building a modernized ClinicalTrials.gov! Visit Beta.ClinicalTrials.gov to try the new functionality.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 17 for:    mesenchymal stem cell | Brazil | Phase 2, 3
Previous Study | Return to List | Next Study

Mesenchymal Stem Cells in Rotator Cuff Repair

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03362424
Recruitment Status : Suspended (Cryogenesis company stopped supplying mesenchymal cells)
First Posted : December 5, 2017
Last Update Posted : October 19, 2022
Sponsor:
Information provided by (Responsible Party):
Eduardo Angeli Malavolta, University of Sao Paulo

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
Randomized clinical study involving 44 patients, evaluating the effect of mesenchymal cells on rotator cuff repair. The primary outcome will be post-operative MRI tendon integrity and secondary outcomes clinical assessment by the UCLA and American Shoulder and Elbow Surgeons (ASES) scales and pain by visual analog scale (VAS).

Condition or disease Intervention/treatment Phase
Rotator Cuff Tear Tendon Injuries Mesenchymal Stem Cell Biological: Mesenchymal stem cell Procedure: Rotator cuff repair Phase 2

Detailed Description:

Rotator cuff tendinopathy is the main cause of shoulder pain and tear of these tendons affects 20% of the population. Although arthroscopic repair leads to satisfactory clinical results, the retear rates varies from 4 to 94%. The main cause of failure after rotator cuff repair is not related to the material used, but to the tissue deficiency and the healing process between the tendon and the bone. After the intervention, the rotator cuff does not restore its original histological characteristics and its fixation occurs through scar tissue with lower biomechanical resistance. There are few clinical studies on the use of mesenchymal cells in rotator cuff repair,, with good results.

The investigators will perform a randomized clinical study involving 44 patients, evaluating the effect of mesenchymal cells on rotator cuff repair. The primary outcome will be post-operative MRI tendon integrity and secondary outcomes clinical assessment by the UCLA and American Shoulder and Elbow Surgeons (ASES) scales and pain by visual analog scale (VAS).

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 44 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized controlled trial
Masking: Single (Outcomes Assessor)
Masking Description: Surgeon and patients not blinded
Primary Purpose: Treatment
Official Title: Mesenchymal Stem Cells in Rotator Cuff Repair - a Randomized Prospective Study
Actual Study Start Date : November 1, 2020
Estimated Primary Completion Date : December 1, 2023
Estimated Study Completion Date : December 1, 2023
Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Mesenchymal stem cell group
rotator cuff repair stem cells
 Biological: Mesenchymal stem cell
Mesenchymal stem cells applies at the end of rotator cuff repair in de active group

Procedure: Rotator cuff repair
Rotator cuff repair
Active Comparator: Control group
rotator cuff repair
 Procedure: Rotator cuff repair
Rotator cuff repair


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. MRI integrity [ Time Frame: 6 months ]
    Sugaya classification


Secondary Outcome Measures :
  1. American Shoulder and Elbow Surgeons Standardized Shoulder Assessment Form (ASES) [ Time Frame: 6, 12 and 24-months ]
    minimum 0 points, maximum 100 points. Higher values are considered best outcomes.

  2. University at California at Los Angeles Shouder Rating Scale (UCLA) [ Time Frame: 6, 12 and 24-months ]
    minimum 3 points, maximum 35 points. Higher values are considered best outcomes.

  3. Visual Analog Scale for Pain (VAS) [ Time Frame: 6, 12 and 24-months ]
    miminum 0 points, maximum 10 points. Higher values are considered worst outcomes.


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   35 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Full thickness posterosuperior rotator cuff tear, of small or medium size, fully repairable at the time of surgery, regardless of size;
  • Pain and / or decreased shoulder function for at least 3 months, with no improvement with non-surgical treatment;
  • Absence of the following changes in MRI:
  • Fat degeneration of the rotator cuff musculature of grade 3 according to the classification of Fuchs (presence of equal or superior amount of fat compared to muscle fibers);
  • Absence of the following changes in radiographs
  • Advanced glenohumeral arthrosis (grades 2, 3 and 4 of Samilson and Prieto
  • Signs of rotator cuff arthropathy, according to Seebauer classification;
  • Skeletal maturity;
  • Absence of surgeries or previous fractures in the shoulder in question;
  • Absence of psychiatric illnesses, fibromyalgia or painful pathologies of the cervical spine;
  • Absence of rheumatic diseases or chronic use of corticosteroids;
  • Absence of active or recent infection;
  • Absence of thrombocytopenia, coagulopathies or chronic use of anticoagulants;
  • Absence of vascular or neurological lesions affecting the upper limb;
  • Absence of pregnancy;
  • Clinical non-compensated comorbidities;
  • Chronic use of corticosteroids;
  • Consent to free and informed consent;
  • Live in Brazil.

Exclusion Criteria:

  • Visualization during the operative event of one or more of the findings:
  • Irreparable rupture of rotator cuff;
  • Subsecapularis tear involving two thirds or more of its extension;
  • Need to open surgery.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03362424


Locations
Layout table for location information
Brazil
Universidade de São Paulo
São Paulo, SP, Brazil, 05403-010
Sponsors and Collaborators
University of Sao Paulo
Investigators
Layout table for investigator information
Principal Investigator: EDUARDO ANGELI MALAVOLTA A Malavolta, PhD MD, PhD, Associate Professor
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Eduardo Angeli Malavolta, Principal investigator, University of Sao Paulo
ClinicalTrials.gov Identifier: NCT03362424    
Other Study ID Numbers: 2.335.243
First Posted: December 5, 2017    Key Record Dates
Last Update Posted: October 19, 2022
Last Verified: October 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Rotator Cuff Injuries
Tendon Injuries
Rupture
Wounds and Injuries
Shoulder Injuries